LADENBURG THALMANN FINANCIAL SERVICES INC. - KERYX BIOPHARMACEUTICALS INC ownership

KERYX BIOPHARMACEUTICALS INC's ticker is KERX and the CUSIP is 492515101. A total of 154 filers reported holding KERYX BIOPHARMACEUTICALS INC in Q2 2015. The put-call ratio across all filers is 0.73 and the average weighting 0.1%.

Quarter-by-quarter ownership
LADENBURG THALMANN FINANCIAL SERVICES INC. ownership history of KERYX BIOPHARMACEUTICALS INC
ValueSharesWeighting
Q3 2018$13,000
+8.3%
3,876
+29.8%
0.00%
Q2 2018$12,0000.0%2,9850.0%0.00%
Q1 2018$12,000
-42.9%
2,985
-33.7%
0.00%
Q4 2017$21,000
-34.4%
4,505
+2.3%
0.00%
Q3 2017$32,000
-17.9%
4,405
-18.5%
0.00%
Q2 2017$39,000
+8.3%
5,405
-8.0%
0.00%
Q1 2017$36,000
+2.9%
5,8750.0%0.00%
Q4 2016$35,000
+12.9%
5,875
+1.7%
0.00%
Q3 2016$31,000
-13.9%
5,775
+3.6%
0.00%
-100.0%
Q2 2016$36,000
+44.0%
5,5750.0%0.00%
Q1 2016$25,000
-10.7%
5,575
+2.0%
0.00%
-100.0%
Q4 2015$28,000
+12.0%
5,466
-19.8%
0.00%0.0%
Q3 2015$25,000
-61.5%
6,815
+4.1%
0.00%0.0%
Q2 2015$65,000
-18.8%
6,545
+4.9%
0.00%
-50.0%
Q1 2015$80,000
-3.6%
6,241
+7.5%
0.00%0.0%
Q4 2014$83,000
+29.7%
5,805
+24.8%
0.00%0.0%
Q3 2014$64,000
-26.4%
4,651
-17.8%
0.00%0.0%
Q2 2014$87,000
-34.6%
5,658
-27.6%
0.00%
-50.0%
Q1 2014$133,000
+24.3%
7,813
-6.2%
0.00%
+33.3%
Q4 2013$107,000
+44.6%
8,332
+17.2%
0.00%0.0%
Q3 2013$74,000
+37.0%
7,111
-1.4%
0.00%
+50.0%
Q2 2013$54,0007,2110.00%
Other shareholders
KERYX BIOPHARMACEUTICALS INC shareholders Q2 2015
NameSharesValueWeighting ↓
VHCP Management, LLC 700,273$10,770,0005.76%
HARVEY CAPITAL MANAGEMENT INC 932,400$14,340,0005.13%
Camber Capital Management LP 3,000,000$46,140,0003.02%
Baupost Group 10,539,986$162,105,0002.64%
SECTORAL ASSET MANAGEMENT INC 3,741,656$57,547,0002.44%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 3,884,409$59,742,0002.40%
Knoll Capital Management, LLC 200,000$3,076,0001.37%
DAFNA Capital Management LLC 92,400$1,421,0001.35%
NORTHPOINTE CAPITAL LLC 892,011$13,719,0001.32%
Rhenman & Partners Asset Management AB 240,000$3,691,0001.10%
View complete list of KERYX BIOPHARMACEUTICALS INC shareholders